# ImmunityBio (formerly NantKwest)

ImmunityBio (formerly NantKwest) is an other based in Culver City, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Culver City, United States
- **Region:** North America
- **Address:** Culver City, CA, United States
- **Assets under management:** Undisclosed
- **Website:** www.nantkwest.com
- **LinkedIn:** https://www.linkedin.com/company/nantkwest

## Regulatory record

- **Reports private funds:** No

## About

ImmunityBio is a commercial-stage biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems. At the core of its strategy is the Cancer BioShield platform, anchored by the IL-15 superagonist ANKTIVA.

## Sectors

- Healthcare Services

## Offices

- Chicago
- San Ramon
- San Diego

## People

- Dr. Patrick Soon-Shiong — Founder, Executive Chairman and Global Chief Scientific and Medical Officer
- Richard Adcock — President and Chief Executive Officer
- Dr. Jim Yong Kim — Vice Chairman
- Hemanth Ramaprakash — PhD, MBA, Investors contact
- Sarah Singleton — Media contact

## Questions

### What is ANKTIVA and how does it work?

ANKTIVA is an FDA-approved immunotherapy for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease. It is administered intravesically and activates NK cells, T cells, and macrophages to attack cancer cells while preserving the immune system. The therapy is now marketed in the U.S. and Saudi Arabia.

### Does ImmunityBio engage in fund commitments or direct investments?

No. ImmunityBio is a development-stage biopharmaceutical company focused on R&D, clinical trials, and commercialization of its own therapeutics. It does not participate in fund commitments or direct external investments. Its financial activities relate to corporate financing, such as non-dilutive debt and equity offerings.

### How does ImmunityBio source its proprietary technology?

ImmunityBio's technology is developed internally via its research team and through partnerships. The company's platform is built on activating multiple immune pathways, including NK cells and T cells, using proprietary constructs and adjuvants. Its science is disclosed in SEC filings and academic presentations.

### What investment stages does ImmunityBio target?

ImmunityBio does not invest; it is a biotech company targeting later-stage clinical development (Phase 2 and Phase 3 trials) and commercialization. Its pipeline includes both early and late-stage programs in bladder cancer, lung cancer, and infectious diseases.

## Related profiles

- [KEYW Corporation](https://altss.com/profile/keyw-corporation)
- [Pilot Wall Group](https://altss.com/profile/pilot-wall-group)

---

Last updated: 2026-08-11T15:07:34.613Z

Canonical page: https://altss.com/profile/nantkwest

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology